Skip to main content

Table 1 Patients’ characteristics and statistical analysis. IS non-responders were defined as patients with no significant improvement of clinical symptoms to the inhalative therapy after 2 weeks

From: Inhalative steroids as an individual treatment in symptomatic lung cancer patients with radiation pneumonitis grade II after radiotherapy – a single-centre experience

  Inhalative steroid non-responders Inhalative steroid responders p-value
n = 6 n = 18
Median age (years) 63.3 65.2 0.680
Range (years) 52–74 50–82
Gender    0.651
Male 4 12  
Female 2 6
UICC stage    
IB 0 1 0.762
IIB 1 2 0.696
IIIA 0 4 0.304
IIIB 2 4 0.662
IV 4 5 0.182
Histological type 0 6  
Squamous cell carcinoma 2 8 0.545
Adenocarcinoma 3 6 0.283
Smoking status    
Non-smoker 1 4 0.634
Former smoker 5 13 0.520
Current smoker 0 1 0.750
Pack years (average) 52 47 0.131
Pre-existing COPD 2 7 0.603
ECOG status before radiotherapy 0   0.590
0 3 10
1 3 8
Spirometry before radiotherapy    
FEV1 (average, l) 1.73 1.8 0.705
VC (average, l) 2.9 2.9 0.544
RAWtot (average, kPas/l) 2.28 3.0 0.630
pO2 (average, mmHg) 70 67 0.686
pCO2 (average, mmHg) 36.8 40.1 0.207
HbCO (average, %) 0.3 2.2 0.077
Hb (average, g/dl) 15.45 14.05 0.424
DLCO (average, mmol/min/kPa) 4.4 4.8 0.701
Median total dose (Gy) 59 63 0.537
Mean lung dose (Gy) 14.9 15.4 0.475
Range 8–20 3–23  
Chemotherapeutic regimen    
None 1 2 0.597
Concurrent 4 16 0.366
Sequential 1 0 0.730